Core Viewpoint - The company has decided to postpone certain fundraising investment projects, specifically the "New Annual Production of 10,000 Tons of Aerospace-Grade High-Temperature Alloy Technology Renovation Project" and the "New R&D Center Project," extending their expected operational readiness date to December 2027 due to various practical considerations [1][10]. Fundraising Overview - The company raised a total of approximately 2.41 billion RMB from its initial public offering, with a net amount of about 2.20 billion RMB after deducting issuance costs [1]. - The funds are managed in a dedicated account to ensure proper usage and compliance with regulations [2]. Investment Project Status - The total investment for the "New Annual Production of 10,000 Tons of Aerospace-Grade High-Temperature Alloy Technology Renovation Project" was adjusted from 100,016.76 million RMB to 80,176.88 million RMB, with a cumulative investment of 45,237.72 million RMB, representing 56.42% of the total [2][3]. Reasons for Project Delay - The delay in the "New Annual Production of 10,000 Tons of Aerospace-Grade High-Temperature Alloy Technology Renovation Project" is attributed to macroeconomic conditions and market demand, as well as the need for stable processing technology [3][4]. - The "New R&D Center Project" is also delayed due to the company's involvement in national-level research projects and limitations in current facilities [4]. Re-evaluation of Projects - The company has conducted a re-evaluation of the necessity and feasibility of continuing the "New R&D Center Project," concluding that it remains aligned with strategic goals despite the delay [4][5]. Strategic Importance of Projects - The development of high-temperature alloys is critical for the aerospace industry, impacting engine performance and reliability, thus necessitating ongoing research and development [5][6]. - Establishing the R&D center is essential for overcoming technical barriers and enhancing product offerings, which will improve the company's competitive edge [6][7]. Policy and Market Support - National policies and industry growth create a favorable environment for the implementation of these projects, aligning with strategic national interests in advanced materials [7][8]. - The company has a strong technical foundation, with numerous patents and research platforms, supporting the successful development of high-temperature alloys [9]. Impact of Project Delay - The postponement of these projects is a cautious decision that does not alter the investment scope or objectives, ensuring no significant adverse effects on the company's operations [10][11].

Core Viewpoint - The company intends to sign a housing lease agreement with Wuxi Yuyuan Industrial Group Co., Ltd. to enhance employee accommodation conditions and attract high-tech talent, involving a rental area of 5,643.52 square meters for a period of five years with a total rental amount of 9.8257 million yuan [1][5][8] Summary by Sections 1. Overview of Related Transactions - The lease agreement aims to improve employee living conditions and overall satisfaction, with a rental price of 1.06 yuan per square meter per day, totaling 9.8257 million yuan for the lease term [1][5] 2. Related Party Information - Wuxi Yuyuan Industrial Group is a related party due to shared control by Pu Yilong, and the transaction does not constitute a major asset restructuring [2][3] 3. Basic Information of the Transaction Target - The leased property is located at No. 69, Dongxing Road, Xishan District, Wuxi, with a total area of 5,643.52 square meters [3][4] 4. Pricing of Related Transactions - The rental price was determined based on a third-party real estate rental consulting report, ensuring fairness and reasonableness in pricing [5][8] 5. Main Content of the Related Transaction Agreement - The agreement stipulates that the landlord will cover property service fees, and the total rental amount for the lease period is 9.8257 million yuan [6][7] 6. Necessity of the Related Transaction and Its Impact - The company has experienced a compound annual growth rate of 6.70% in employee numbers over the past three years, necessitating the expansion of employee accommodation [8] 7. Review Procedures for Related Transactions - The independent directors and the board of supervisors have approved the lease agreement, and it will be submitted for shareholder approval, with related shareholders abstaining from voting [8][9]

智通财经APP获悉，近期沪指再度刷新十年高点，沪深交易成交量破三万亿。 华西证券指出，市场放量大涨，是资金情绪正盛的表现。同时，隐含波动率大幅上升，也是投机热度快 速上升的信号。 中信建投发布研报称，政策/会议信号为证券板块超额收益的核心驱动。长期以来，证券板块在A股地位 非常重要，但主动权益投资机构的配置比例偏低，但研究发现，证券板块相对于宽基指数的超额收益投 资机会远多于绝对收益型机会，该板块配置价值存在低估。 中资券商板块相关港股： 中信建投证券(06066)、中金公司(03908)、广发证券(01776)、东方证券(03958)、光大证券(06178)、中信 建投(06066)、申万宏源(06806)、中州证券(01375)、国联民生(01456)等。 往后看，若行情和隐含波动率加速上涨，行情在短期内或将调整以回归理性；若市场延续"慢牛"格局， 同时隐含波动率变化不大或显著回落，行情波动的时点可能较前一种情况有所延后。不过，短期行情与 资金交易行为相关，而牛市的三条中长期逻辑依旧相对牢固。这意味着，若以上中长期逻辑不变，调整 仍是机会，牛市思维值得继续保持。 ...

国联民生证券承销保荐有限公司（以下简称"保荐机构"）作为碧兴物联科 技（深圳）股份有限公司（以下简称"碧兴物联"、"公司"）首次公开发行股 票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上海 证券交易所科创板上市公司自律监管指引第1号——规范运作》和《上市公司募集 资金监管规则》等法律法规有关规定，对碧兴物联使用自有资金支付募投项目所 需资金并以募集资金等额置换的事项进行了核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意碧兴物联科技（深圳）股份有限公司 首次公开发行股票注册的批复》（证监许可[2023]1009号）同意注册，公司首次公 开发行人民币普通股（A股）19,630,000.00股，每股发行价格36.12元，募集资金总 额为人民币709,035,600.00元，扣除不含税发行费用人民币85,592,015.58元，实际募 集资金净额为人民币623,443,584.42元，该募集资金已于2023年8月4日到账。上述 募集资金到位情况已经立信会计师事务所（特殊普通合伙）审验，并出具了信会 师报字[2023]第ZL10015号验资报告。 二、募集资金投资项目 ...

证券代码：601456 证券简称：国联民生 公告编号：2025-055 号 国联民生证券股份有限公司 关于子公司重大诉讼的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 原告：李立群等 1,618 名投资者（投资者人数已经济南中院审查确认） 代表人：李立群、万云、孙静、田庆龙、李明臣 被告：龙力生物、程少博等 12 名自然人、国联民生承销保荐、立信会计师 事务所（特殊普通合伙）（以下简称"立信会计"） 案由：证券虚假陈述责任纠纷 诉讼方式：普通代表人诉讼 公司分别于 2022 年 8 月 6 日披露了《关于子公司重大诉讼的公告》（公告编 1 案件所处的诉讼阶段：一审判决 上市公司所处的当事人地位：国联民生证券股份有限公司（以下简称 "公司"）全资子公司国联民生证券承销保荐有限公司（以下简称"国 联民生承销保荐"，曾用名：华英证券有限责任公司）为 15 名被告之 一。 涉案的金额：一审判决原告及原告代表人对被告山东龙力生物科技股 份有限公司（以下简称"龙力生物"）享有投资差额损失、通知费及律 师费债权数 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （股份代號：01456） （於中華人民共和國成立的股份有限公司） 關於子公司重大訴訟的進展公告 近日，國聯民生承銷保薦收到山東省濟南市中級人民法院（「濟南中院」或「本院」）送 達的《民事判決書》，現將相關信息公告如下： 一、訴訟的基本情况 1 原告： 李立群等1,618名投資者（投資者人數已經濟南中院審查確認） 代表人： 李立群、萬雲、孫靜、田慶龍、李明臣 被告： 山東龍力生物科技股份有限公司（「龍力生物」）、程少博等12名 自然人、國聯民生承銷保薦、立信會計師事務所（特殊普通合夥） （「立信會計」） 案由： 證券虛假陳述責任糾紛 訴訟方式： 普通代表人訴訟 二、原告訴訟請求、事實和理由 （一）原告訴訟請求 （二）訴訟事實和理由 原告訴稱，因龍力生物的虛假陳述行為，中國證券監督管理委員會對龍力 生物等主體作出相應處罰。各原告在相關期間買入並持有龍力生物股票的 損失與龍力生物虛假陳述行為之間存在因果關係。 ...

Product Prices and Market Performance - Overall demand has decreased due to the pharmaceutical environment, but the three main intermediate products of the company have shown varied performance. The price of thiocyanate erythromycin has risen slightly, with a single-digit increase since the beginning of the year, and is expected to remain stable in the second half of the year. The price of cephalosporin products is stable and is expected to maintain the current situation in the second half. The price of penicillin has decreased since the beginning of the year, but with increasing industry concentration, it is becoming more difficult for small companies to enter the market. An increase in demand is expected in the fourth quarter, which may improve the situation [1]. Synthetic Biology and Project Progress - Sales of synthetic biology products are steadily advancing, with the company achieving a revenue of 22.32 million yuan in the first half of the year. With adjustments and releases in production capacity, future sales are expected to increase. The methanol protein project has undergone trials in a 30m³ fermentation tank, with initial results available and samples sent to downstream manufacturers for testing. The company is also actively applying for qualifications from the Ministry of Agriculture and Rural Affairs [2]. Overseas Capacity and Domestic Planning - After assessment, the company has decided to postpone its entry into Kazakhstan due to several uncontrollable risks. The first phase of the company is in a rapid development stage, and the second phase will be determined based on the R&D progress of the Shanghai Research Institute and the release of first-phase capacity [3]. Order Expectations and Capital Expenditure - The company anticipates growth in orders with Kelun Yongnian Company for ergotamine. There are no significant capital expenditures expected in the short term, with fixed asset depreciation for the first half of 2025 amounting to 273 million yuan, an increase of 22 million yuan year-on-year. Starting in 2026, the main equipment depreciation is expected to decrease significantly, with a projected reduction of tens of millions if no new fixed assets are added by the end of 2027 [4]. R&D and Product Selection Planning - Future R&D will focus on four main areas: traditional product synthesis and biological modification; technology enhancement and cost reduction for delivered products; efficient biological utilization of C1/C2 resources; and the development of amino acids and vitamin products [5]. Cost Trends and Import-Export Situation - The price of the main raw material, corn, is expected to rise to 1.8 - 1.9 yuan/kg in November. Energy costs, particularly coal prices, have decreased compared to 2024 and are expected to remain stable in the coming years. The export amount has increased by approximately 25% compared to the same period last year, mainly due to increased exports of thiocyanate and 6-APA, while cephalosporin exports have slightly decreased. Exports are primarily directed towards India and Hong Kong, with tariffs having minimal impact on the company's exports [6]. Gross Margin and Production Efficiency - With the increase in synthetic biology product volume and the application of AI technology, the company has room for improvement in gross margin. AI-controlled fermentation tank output exceeds the control group by 3% - 5%, reducing production fluctuations and enhancing R&D efficiency. The overall gross margin for the company in the first half of 2025 was 35.90%, a year-on-year increase of 0.55%, while the gross margin for pharmaceutical intermediates was 38.64%, a year-on-year increase of 1.37% [7]. Expenses and Performance Outlook - The sales expense ratio for the first half of 2025 was 0.58%, an increase of 0.21% year-on-year, and is expected to remain stable in the second half. The management expense ratio was 3.37%, an increase of 0.13% year-on-year, while the financial expense ratio was 0.67%, a decrease of 0.19% year-on-year. The company is facing performance pressure this year due to the impact of penicillin prices, with expectations of a decline compared to last year. However, in 2026, with the increase in synthetic biology product volume and the recovery of penicillin prices, performance and profits are expected to improve [8].

Group 1 - The core point of the news is that Shuangyuan Technology (688623.SH) is currently experiencing a decline in stock price, closing at 68.72 yuan with a drop of 3.40%, resulting in a total market capitalization of 4.064 billion yuan, indicating that the stock is in a state of breaking issue [1] - The stock was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on June 8, 2023, with an initial offering price of 125.88 yuan per share and a total issuance of 14.7857 million shares [1][2] - On its first trading day, the stock reached a peak price of 120.00 yuan but has since experienced fluctuations leading to a downward trend [2] Group 2 - Shuangyuan Technology raised a total of 1.861224 billion yuan through its initial public offering, with a net amount of 1.6663587 billion yuan after deducting issuance costs, which exceeded the originally planned fundraising amount by 1.0147809 billion yuan [2] - The company intended to use the raised funds for projects including the construction of an intelligent measurement and control equipment production base, a research and development center, a marketing network, and to supplement working capital [2] - The underwriting institution for Shuangyuan Technology is Minsheng Securities Co., Ltd., which received a total underwriting fee of 170.7192 million yuan from the issuance [2][3] Group 3 - The strategic placement of shares involved Minsheng Securities Investment Co., Ltd., which acquired 476,644 shares, accounting for 3.22% of the total issuance, with an investment amount of approximately 60 million yuan [3] - Minsheng Securities Investment Co., Ltd. has committed to holding the allocated shares for a period of 24 months from the date of the initial public offering and listing [3]

Core Viewpoint - The report highlights the changes in the Hong Kong Stock Connect holdings, indicating significant increases and decreases in ownership percentages for various companies, which may signal potential investment opportunities or shifts in market sentiment. Group 1: Increased Holdings - Shandong Molong (00568) saw the largest increase in Hong Kong Stock Connect holdings, rising by 3.41% to a total holding of 58.38% [2] - ZTE Corporation (00763) experienced a 2.52% increase, bringing its holding to 54.86% [2] - Lens Technology (06613) increased by 2.22%, with a current holding of 11.01% [2] - Other notable increases include Southern Hang Seng Technology (03033) at +2.08% (60.66%) and Beijing Jingcheng Machinery Electric Company (00187) at +1.35% (49.54%) [2] Group 2: Decreased Holdings - Hang Seng China Enterprises (02828) had the largest decrease, down by 2.31% to 1.02% [2] - The Tracker Fund of Hong Kong (02800) decreased by 0.74%, now holding 1.87% [2] - Li Jin Technology (00558) saw a reduction of 0.69%, with a holding of 14.36% [2] - Other significant decreases include Ping An Good Doctor (01833) at -0.65% (19.25%) and Beijing North Star Company (00588) at -0.59% (41.42%) [2] Group 3: Five-Day Changes - Over the last five trading days, ZTE Corporation (00763) had the highest increase in holdings at +7.26% (54.86%) [3] - Longpan Technology (02465) increased by 6.03% to 51.76% [3] - Tongyuan Kang Pharmaceutical-B (02410) rose by 5.38%, now at 14.68% [3] - Significant decreases included Dongyang Sunshine Pharmaceutical (06887) at -3.85% (44.05%) and Zhejiang Shibao (01057) at -2.73% (55.74%) [3] Group 4: Twenty-Day Changes - Longfei Optical Fiber and Cable (06869) had the largest increase over twenty days at +22.04% (56.07%) [4] - Meizhong Jiahe (02453) increased by 12.55% to 37.75% [4] - Other notable increases include Yimai Sunshine (02522) at +11.66% (40.40%) and Kanglong Chemical (03759) at +9.51% (59.33%) [4] - Decreases over twenty days included Chongqing Steel (01053) at -5.91% (32.47%) and Dongfang Electric (01072) at -5.60% (37.80%) [4]

证券日报网讯 8月25日晚间，国联民生发布公告称，近日，国联民生证券股份有限公司全资子公司国联 民生证券承销保荐有限公司完成法定代表人变更登记手续，其法定代表人由葛小波变更为徐春，并取得 了上海市市场监督管理局换发的营业执照。 （文章来源：证券日报） ...